

# Introduction to Infectious Disease Data

Clinic on the Meaningful Modeling of Epidemiological Data, 2018  
African Institute for Mathematical Sciences  
Muizenberg, South Africa  
May-June, 2019

Thumbi Mwangi, PhD  
Washington State University/University of Nairobi

Faikah Bruce  
Steve Bellan  
Juliet Pulliam

[Slide set citation: https://doi.org/10.6084/m9.figshare.5044603.v4](https://doi.org/10.6084/m9.figshare.5044603.v4)

# Goals

- Understand case definitions - infection, disease, infectious diseases
- Understand approaches to collection of infection and disease data
- Metrics to measure presence and spread of infectious diseases

How would you define:


- Infection?
- Disease?
- Infectious disease?

# Disease

A deviation from the normal physiological status of an organism that negatively affects its survival or reproduction




## What kills East African Zebu calves during their first year of life?




**Figure 6 Definitive aetiological causes of death.** A total of 88 deaths occurred during the study. Five of these were attributed to non-infectious causes (trauma, mis-mothering and cassava poisoning). East Coast Fever was the main cause of death, followed by haemonchosis and heartwater disease. For 25 deaths, a definitive aetiological cause of death could not be determined.

# Infectious Disease

A disease in one organism (the host) that is caused by another organism (pathogen or parasite) which has entered the host's body



Ebola Virus



Tuberculosis Bacteria



HIV

Pathogen: Microorganism that causes disease  
(virus, bacteria, parasite)




- Unravel patterns of disease
- Identify the risk factors for disease (host factors and non-host factors)
- Control options

...from infection to disease....

What is the difference between:

- Incubation period?
- Latent period?
- Infectious period?

# Infection to disease



**Table 5.3. Overview of relevant outcomes from all other data sources: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Red Book (RB), Quick Reference guide (RG), Richardson 2001 (R2001)**

Disease/agent	Incubation period	Period of infectiousness	Period of shedding	Exclusion period	Reference
<b>Vaccine preventable diseases</b>					
Measles	<b>WHO:</b> 7–18 (often, 10–12) days from exposure to the onset of fever [121]; <b>RB:</b> Generally 8–12 days from exposure to onset of symptoms; <b>CDC:</b> 7–21 (14) days to a rash [122–124]; 10–12 days to prodrome [123, 125] <b>R2001:</b> 6–19 (13) days	<b>WHO:</b> 4 days before the rash until 1–2 days after a rash [121]; <b>RB:</b> 4 days before the rash to 4 days after a rash; <b>CDC:</b> 4 days before to 4 days after a rash onset [123–125] <b>R2001:</b> ND (but at least 1–2 days before a rash)	<b>WHO:</b> Following a rash onset, measles excretes for very short period (about 5 days) [126]; <b>CDC:</b> Beginning with the prodrome until 3–4 days after a rash onset; <b>R2001:</b> -2 to +3 days	<b>RB:</b> Until 24 hours after treatment has been initiated; <b>RG:</b> At least 2 weeks after a rash in the last case for unimmunised people who have been exempted from measles immunised within 72 hr of exposure; <b>CDC:</b> 4 days after a rash for cases; 21 days after a rash in the last case for persons who have been exempted from measles vaccination within the appropriate time; <b>R2001:</b> 5 days from onset of a rash	[121–126]
Seasonal influenza	<b>WHO:</b> 1–4 (average, 2) days [170]; <b>RB:</b> 1–4 (average, 2) days; <b>CDC:</b> 1–4 (average, 2) days [123, 124, 130]; <b>R2001:</b> 1–3 (median, 1.5) days	<b>WHO:</b> Shortly before onset of symptoms and last into the second week [170]; <b>RG:</b> From the day before symptoms appear until at least 7 days after the onset of flu, although virus shedding can be longer; <b>CDC:</b> Adults can transmit 1 day before and 5–7 days after symptoms [124], Children can transmit for over 10 days [123]	<b>WHO:</b> Young children: up to 21 days [171]; <b>CDC:</b> 5–10 days [123], Children: >10 days after symptom onset [124], Peak usually occurs from 1 day before onset of symptoms to 3 days after [130]; <b>R2001:</b> 7–12 days, mean 9 days	<b>RG:</b> No need to exclude, unless the child is unable to participate, meets other exclusion criteria such as fever with behaviour change	[123, 124, 130, 170, 171]

Reference: [European Centre for Disease Prevention and Control. Systematic review on the incubation and infectiousness/shedding period of communicable diseases in children. Stockholm: ECDC; 2016](#)



**Relationship Between Clinical Signs and Transmission of an Infectious Disease and the Implications for Control**

Bryan Charleston, *et al.*  
*Science* **332**, 726 (2011);  
 DOI: 10.1126/science.1199884

REPORTS

# Relationship Between Clinical Signs and Transmission of an Infectious Disease and the Implications for Control

Bryan Charleston,<sup>1\*</sup> Bartlomies M. Bankowski,<sup>1</sup> Simon Gubbins,<sup>1</sup> Margo E. Chase-Topping,<sup>2</sup> David Schley,<sup>1</sup> Richard Howey,<sup>2</sup> Paul V. Barnett,<sup>1</sup> Debi Gibson,<sup>1</sup> Nicholas D. Juleff,<sup>1</sup> Mark E. J. Woolhouse<sup>2</sup>

Control of many infectious diseases relies on the detection of clinical cases and the isolation, removal, or treatment of cases and their contacts. The success of such “reactive” strategies is influenced by the fraction of transmission occurring before signs appear. We performed experimental studies of foot-and-mouth disease transmission in cattle and estimated this fraction at less than half the value expected from detecting virus in body fluids, the standard proxy measure of infectiousness. This is because the infectious period is shorter (mean 1.7 days) than currently realized, and animals are not infectious until, on average, 0.5 days after clinical signs appear. These results imply that controversial preemptive control measures may be unnecessary; instead, efforts should be directed at early detection of infection and rapid intervention.

# Case definition

“a set of standard criteria for deciding whether a person has a particular disease [or infection]”



# 2001 Foot & Mouth Disease outbreak in the UK



Image source: <https://www.bbc.com/news/17818367>


**Person:**

**Place:**

**Time:**

**Clinical description:**

- First case – 19<sup>th</sup> February, 2001 – ante-mortem examination of pigs in an abattoir in Essex
- 21<sup>st</sup> Feb, 2001 – European Union ban on all British exports of livestock, meat and animal products
- 23<sup>rd</sup> Feb, 2001 – case confirmed in pig from Northumberland –case definition\*\*)
- 24<sup>th</sup> Feb, 2001 – case in Devon, then Cornwall, and Scotland
- By 16<sup>th</sup> March, 2001 - the number of cases was at 240



23/02 – movement restrictions

22/03 – welfare cull




23/03 – 3km cull policy

29/03 – 24/48hour slaughter on suspicion policy and  
contiguous premises (<3km from infected premises) cull

26/04 – CP cull relaxed

23/07 – hotspots targeted


30/07 – last reported case



# A “case” study



West Africa



Source: New England Journal of Medicine

# Case definition


“a set of standard criteria for deciding whether a person has a particular disease [or infection]”

**Person:** Residents of Meliandou, recent visitors to Meliandou


**Place:** West Africa, Guinea

**Time:** On or after November 15, 2013

**Clinical description:** Elevated body temperature or subjective fever or symptoms, including severe headache, fatigue, muscle pain, vomiting, diarrhea, abdominal pain, or unexplained hemorrhage









Dec. 30, 2013–May 4, 2014

**The Outbreak Begins**



May 5–Aug. 3, 2014


**New Cases Rise Rapidly**




Aug. 4, 2014–Jan. 4, 2015

**W.H.O. Sounds the Alarm**

**Average new cases each week**







***Clinical disease (that which comes to the attention of the clinician) is often only a 'tip of the iceberg' compared to the number of 'submerged' cases that go undiagnosed and unreported***

John M. Last







**Confirmed case**: signs and symptoms *plus* laboratory confirmation

**Probable case**: signs and symptoms in an individual meeting person, place, and time criteria *plus* contact with a known case *or* more specific clinical signs

**Possible case**: signs and symptoms in an individual meeting person, place, and time criteria *plus* a physician diagnosis

**Suspect case**: signs and symptoms in an individual meeting person, place, and time criteria

**Not a case**: failure to fulfill the criteria for a confirmed, probable, possible, or suspect case

# Case definition

“a set of standard criteria for deciding whether a person has a particular disease [or infection]”

**Person:**

**Place:**

**Time:**

**Clinical description:**

# Case definition

“a set of standard criteria for deciding whether a person has a particular disease [or infection]”

**Person:** Residents of Meliandou, recent visitors to Meliandou

**Place:** West Africa, Guinea

**Time:** On or after November 15, 2013

**Clinical description:** Elevated body temperature or subjective fever or symptoms, including severe headache, fatigue, muscle pain, vomiting, diarrhea, abdominal pain, or unexplained hemorrhage

# Case definition for Ebola

- Person:** Residents of and recent visitors to West Africa, including Senegal, Guinea, Sierra Leone and Liberia, as well as their close contacts or others in their community
- Place:** Worldwide
- Time:** On or after November 15, 2013
- Clinical Description:** Illness with onset of fever and no response to treatment for usual causes of fever in the area, and at least one of the following signs: bloody diarrhoea, bleeding from gums, bleeding into skin (purpura), bleeding into eyes and urine.


# Goals

- Defining a case
- Different approaches to data collection and presentation.
- Metrics to describe the spread of the disease

# Ways of collecting data on cases

Surveillance

+ Contact Tracing/Outbreak investigation





# Ways of collecting data on cases

- Passive
- Active

## Epidemiological studies

- Case-series
- Case-control
- Cohort
- Outbreak investigations


# Goals

- Defining a case
- Different approaches to data collection and presentation.
- Metrics to describe the spread of the disease


# Incidence of disease

Weekly incidence of confirmed, probable and suspected Ebola cases in West Africa


**A West Africa**




**B Guinea**



**C Liberia**





**D Sierra Leone**



# Incidence of Infection


Infectivity = 1

(everyone exposed becomes infected)



# Incidence of infection

Mathematical expression?



## SEIR Model

$$\frac{dS}{dt} = \nu - \frac{\beta SI}{N} - \mu S$$

$\nu$  birth rate

$$\frac{dE}{dt} = \frac{\beta SI}{N} - \sigma E - \mu E$$

$\mu$  mortality rate

$$\frac{dI}{dt} = \sigma E - \gamma I - \mu I$$


$\sigma$  1 / latent period

$$\frac{dR}{dt} = \gamma I - \mu R$$

$\gamma$  1 / infectious period

$\beta$  transmission coefficient

# Prevalence



$$\frac{E + I}{N}$$

Mathematical expression?

## SEIR Model

$$\frac{dS}{dt} = \nu - \frac{\beta SI}{N} - \mu S$$

$\nu$  birth rate

$$\frac{dE}{dt} = \frac{\beta SI}{N} - \sigma E - \mu E$$

$\mu$  mortality rate

$$\frac{dI}{dt} = \sigma E - \gamma I - \mu I$$

$\sigma$  1 / latent period

$$\frac{dR}{dt} = \gamma I - \mu R$$


$\gamma$  1 / infectious period

$\beta$  transmission coefficient


Prevalence of infection

Prevalence of antibodies  
(seroprevalence)

# Prevalence



# Seroprevalence



## SEIR Model

$$\frac{dS}{dt} = \nu - \frac{\beta SI}{N} - \mu S$$

$\nu$  birth rate

$$\frac{dE}{dt} = \frac{\beta SI}{N} - \sigma E - \mu E$$

$\mu$  mortality rate

$$\frac{dI}{dt} = \sigma E - \gamma I - \mu I$$

$\sigma$  1 / latent period

$$\frac{dR}{dt} = \gamma I - \mu R$$

$\gamma$  1 / infectious period

$\beta$  transmission coefficient

Mathematical expression?

Prevalence of infection

Prevalence of antibodies  
(seroprevalence)



# Seroprevalence

Can be related to:


- \* Prevalence of infection
- \* Past exposure

May or may not be:

- \* Prevalence of resistance
- \* Specific to infection of interest

# Seroprevalence

## Prevalence of IgG Antibodies against Measles



Source: Matter 1997; EJE; 13:61-66

Can be related to:

- Prevalence of infection
- Past exposure

May or may not be:

- Prevalence of resistance
- Specific to infection

# Levels of data aggregation


Aggregated data

De-identified data


Personally identifying data


# Levels of data aggregation

De-identified data



Aggregated data






**Figure 4** Life lines for each calf showing the time of recruitment, routine examinations and clinical episodes or deaths over the 3 years of the IDEAL project. Black dot=recruitment date, grey bar=weekly visit, grey circle=clinical episode; red dot= died and blue dot = euthanised.

## Investigation line-list

Case ID	Age (Yrs)	Gender	Symptoms onset	Symptoms	Lab sample collected	Date sample collection	Date Hospitalized	Date discharged	Fatal case	Date of death
Case 1	7	Male	2/18/14	papule/edema	X	x	2/20/14	2/24/14	x	x
Case 2	31	Male	2/20/14	papule	X	x	2/20/14	2/24/14	x	x
Case 3	65	Female	2/21/14	papule	Skin swab	2/28/14	x	x	x	x
Case 4	32	Male	2/18/14	diarrhea	X	x	2/21/14	x	Yes	2/21/14
Case 5	24	Male	2/17/14	diarrhea/vomiting	X	x	x	x	Yes	2/18/14
Case 6	48	Male	2/16/14	vomiting/painful swallowing	Oropharyngeal swab	2/28/14	x	x	x	x

### Anthrax outbreak – Kenya 2014

# Visualizing data before R...





This presentation is made available through a Creative Commons Attribution-Noncommercial license. Details of the license and permitted uses are available at <http://creativecommons.org/licenses/by/3.0/>



© 2014-2019 International Clinics on Infectious Disease Dynamics and Data

[Thumbi SM, Bruce F, Bellan SE, Pulliam JRCP. "Introduction to Infectious Disease Data" Clinic on the Meaningful Modeling of Epidemiological Data. https://doi.org/10.6084/m9.figshare.5044603.v4](https://doi.org/10.6084/m9.figshare.5044603.v4)

Attribution:

Thumbi SM, Bruce F, Bellan SE, Pulliam JRCP

Clinic on the Meaningful Modeling of Epidemiological Data

Source URL:

<https://doi.org/10.6084/m9.figshare.5044603.v4>

For further information please contact [figshare@ici3d.org](mailto:figshare@ici3d.org).



**AIMS**

African Institute for  
Mathematical Sciences  
SOUTH AFRICA



**SACEMA**  
DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis



**UNIVERSITY OF GEORGIA**  
College of Public Health